Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SNDX Stock Forecast 2026-2027
$20.72
Current Price
$1.78B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SNDX Price Targets
+170.3%
To High Target of $56.00
+83.4%
To Median Target of $38.00
+30.3%
To Low Target of $27.00
SNDX Price Momentum
-6.3%
1 Week Change
+1.7%
1 Month Change
+64.4%
1 Year Change
-1.4%
Year-to-Date Change
-8.8%
From 52W High of $22.73
+141.5%
From 52W Low of $8.58
📊 TOP ANALYST CALLS
Did SNDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Syndax is one of their latest high-conviction picks.
Latest SNDX Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, SNDX has a bullish consensus with a median price target of $38.00 (ranging from $27.00 to $56.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $20.72, the median forecast implies a 83.4% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Zelin at BTIG, projecting a 170.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SNDX Analyst Ratings
14
Buy
0
Hold
0
Sell
SNDX Price Target Range
Low
$27.00
Average
$38.00
High
$56.00
Current: $20.72
Latest SNDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SNDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $56.00 |
| Nov 24, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $35.00 |
| Nov 12, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $33.00 |
| Nov 4, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $22.00 |
| Nov 4, 2025 | UBS | David Dai | Buy | Maintains | $38.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $40.00 |
| Oct 27, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $56.00 |
| Oct 16, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Assumes | $40.00 |
| Sep 19, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $56.00 |
| Sep 10, 2025 | Stifel | Bradley Canino | Buy | Reinstates | $44.00 |
| Sep 5, 2025 | Goldman Sachs | Corinne Johnson | Buy | Maintains | $24.00 |
| Sep 4, 2025 | Guggenheim | Bradley Canino | Buy | Initiates | $34.00 |
| Aug 5, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $51.00 |
| Aug 5, 2025 | BTIG | Justin Zelin | Buy | Maintains | $56.00 |
| Jul 15, 2025 | UBS | David Dai | Buy | Maintains | $35.00 |
| Jul 10, 2025 | Goldman Sachs | Corinne Johnson | Buy | Initiates | $18.00 |
| May 6, 2025 | Scotiabank | George Farmer | Sector Perform | Maintains | $17.00 |
| May 6, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $32.00 |
| Mar 20, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $41.00 |
| Mar 4, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $39.00 |
Syndax Pharmaceuticals Inc. (SNDX) Competitors
The following stocks are similar to Syndax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Syndax Pharmaceuticals Inc. (SNDX) Financial Data
Syndax Pharmaceuticals Inc. has a market capitalization of $1.78B with a P/E ratio of -5.5x. The company generates $111.30M in trailing twelve-month revenue with a -279.9% profit margin.
Revenue growth is +267.0% quarter-over-quarter, while maintaining an operating margin of -125.2% and return on equity of -129.3%.
Valuation Metrics
Market Cap
$1.78B
Enterprise Value
$1.69B
P/E Ratio
-5.5x
PEG Ratio
0.2x
Price/Sales
16.2x
Growth & Margins
Revenue Growth (YoY)
+267.0%
Gross Margin
+95.4%
Operating Margin
-125.2%
Net Margin
-279.9%
EPS Growth
+267.0%
Financial Health
Cash/Price Ratio
+25.2%
Current Ratio
4.6x
Debt/Equity
299.3x
ROE
-129.3%
ROA
-39.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Syndax Pharmaceuticals Inc. (SNDX) Business Model
About Syndax Pharmaceuticals Inc.
What They Do
Develops innovative cancer therapies.
Business Model
Syndax Pharmaceuticals generates revenue through the development and commercialization of its cancer treatment therapies. The company focuses on creating investigational drugs that enhance immune response and target genetic factors of cancer, aiming for significant improvements in treatment efficacy.
Additional Information
Syndax is engaged in research on epigenetic therapies and immuno-oncology, contributing to advancements in cancer therapeutics. The company seeks partnerships to further its research and development efforts, positioning itself as a key player in the pharmaceutical and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
270
CEO
Mr. Michael A. Metzger M.B.A.
Country
United States
IPO Year
2016
Website
syndax.comSyndax Pharmaceuticals Inc. (SNDX) Latest News & Analysis
Latest News
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
23 hours ago
Quick Summary
Syndax Pharmaceuticals (SNDX) has presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its developments and strategies.
Why It Matters
Syndax Pharmaceuticals' presentation at a major healthcare conference can signal potential advancements in their projects, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Syndax reported preliminary 4Q25 net revenues of $44M for Revuforj and $56M for Niktimvo, with full year revenues of $125M and $152M, respectively. Company ended 2025 with $394M in cash.
Why It Matters
Preliminary revenue growth for Revuforj and Niktimvo indicates strong market demand, while substantial cash reserves suggest financial stability. Positive trends may boost investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Syndax Pharmaceuticals' CEO, Michael A. Metzger, will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. PT/6:00 p.m. ET.
Why It Matters
Syndax Pharmaceuticals' CEO presenting at a major healthcare conference could signal upcoming developments or partnerships, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Syndax Pharmaceuticals and WODA are launching a Managed Access Program for Revuforj® in regions where it's not commercially available, including parts of Eurasia, Europe, Israel, and Latin America.
Why It Matters
The expansion of Revuforj's access could drive revenue growth for Syndax Pharmaceuticals by tapping into new markets and increasing patient adoption, potentially boosting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Syndax Pharma: Continuing Execution In AML
27 days ago
Quick Summary
Syndax Pharmaceuticals has two FDA-approved drugs, Revuforj and Niktimvo. Revuforj shows high efficacy in AML and is gaining market share, with manageable safety data supporting a strong buy rating.
Why It Matters
Syndax's FDA-approved drugs enhance its market position, with Revuforj showing strong efficacy in AML. Positive data on safety boosts confidence, likely increasing stock appeal and investment interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Syndax Pharmaceuticals' Revuforj® (revumenib) won Best New Drug at the 2025 Scrip Awards, highlighting its significance in cancer therapy development.
Why It Matters
Syndax's Revuforj® winning Best New Drug enhances its market position, potentially boosting sales and investor confidence in the company's future growth and innovation in cancer therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SNDX Stock
What is Syndax Pharmaceuticals Inc.'s (SNDX) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Syndax Pharmaceuticals Inc. (SNDX) has a median price target of $38.00. The highest price target is $56.00 and the lowest is $27.00.
Is SNDX stock a good investment in 2026?
According to current analyst ratings, SNDX has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SNDX stock?
Wall Street analysts predict SNDX stock could reach $38.00 in the next 12 months. This represents a 83.4% increase from the current price of $20.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Syndax Pharmaceuticals Inc.'s business model?
Syndax Pharmaceuticals generates revenue through the development and commercialization of its cancer treatment therapies. The company focuses on creating investigational drugs that enhance immune response and target genetic factors of cancer, aiming for significant improvements in treatment efficacy.
What is the highest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
The highest price target for SNDX is $56.00 from Justin Zelin at BTIG, which represents a 170.3% increase from the current price of $20.72.
What is the lowest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
Price targets from Wall Street analysts for SNDX are not currently available. The stock is trading at $20.72.
What is the overall SNDX consensus from analysts for Syndax Pharmaceuticals Inc.?
The overall analyst consensus for SNDX is bullish. Out of 21 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.00.
How accurate are SNDX stock price projections?
Stock price projections, including those for Syndax Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 9:52 PM UTC